60 Degrees Pharmaceuticals Inc(SXTP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 29 at 7:56 AM ET (Korea 9/29 20:56)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -6.19 | Insider Own | 24.84% | Shs Outstand | 2.7M | Perf Week | 23.76% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | 0.85% | Shs Float | 2.6M | Perf Month | 17.92% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.61 | Inst Own | 9.93% | Short Float | 8.18% | Perf Quarter | -29.78% |
| Income | -0.01B | P/S | 3.63 | EPS this Y | 73.06% | Inst Trans | 4.97% | Short Ratio | 2.51 | Perf Half Y | -16.67% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -191.39% | Short Interest | 0.22M | Perf YTD | -38.52% |
| Book/sh | -2.61 | P/C | 4.3 | EPS past 3/5Y | 64.19% 37.74% | ROE | -321.29% | 52W High | -85.5% ($8.62) | Perf Year | -77.02% |
| Cash/sh | 0.29 | P/FCF | - | Sales past 3/5Y | 40.21% -11.18% | ROIC | -293.13% | 52W Low | 48.82% ($0.84) | Perf 3Y | -99.3% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 86.32% | Gross Margin | 26.32% | Volatility(W/M) | 10.07% 10.14% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 10.74 | Sales Y/Y TTM | 24.77% | Oper. Margin | -708.59% | ATR (14) | 0.1 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.78 | EPS Q/Q | 81.96% | Profit Margin | -709.19% | RSI (14) | 65.31 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.32 | Sales Q/Q | -32.47% | SMA20 | 24.73% ($1) | Beta | 2.51 | Target Price | $3.7 |
| Payout | - | Debt/Eq | 0.06 | Earnings | 2026/8/14 | SMA50 | 9.19% ($1.14) | Rel Volume | 0.93 | Prev Close | $1.17 |
| Employees | 5 | LT Debt/Eq | 0.06 | EPS/Sales Surpr. | -22.45% 12.38% | SMA200 | -36.57% ($1.97) | Avg Volume(3M) | 0.09M | Price | $1.25 |
| IPO | 2023/7/12 | Option/Short | No/Yes | Trades | 481 | Volume | 80,259 | Change | 6.84% |
💊 60 Degrees Pharmaceuticals () is a specialty pharmaceutical company headquartered in Washington, D.C., focused on the prevention and treatment of infectious diseases. Its flagship product is Arakoda (tafenoquine), a malaria prevention drug. Although its revenue is very small, it is a micro-cap stock pursuing a strategy of boosting margins through a cash-pay model.
Over the past 1 year, on the lower side
85% below its 1-year high.
Traded about as much as usual That is 93% of its average volume.
SXTP has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +73.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $363. Peers typically go for $1,227.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -99.3%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 9.9%.
Tap to view numbers
It ranks #555 of 592 in the industry
Based on market cap of $4M.
GRI#552 GRI Bio Inc $5M PER - 
DRMA#553 Dermata Therapeutics Inc $5M PER - 
PMCB#554 PharmaCyte Biotech Inc $5M PER - SXTP#555 60 Degrees Pharmaceuticals Inc $4M PER - 
DCOY#556 Decoy Therapeutics Inc $4M PER - 
FAQ
What kind of company is SXTP?
SXTP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SXTP?
The market cap of SXTP is approximately $4M, ranking 5,722 within its sector.
What is the 52-week high and low for SXTP?
SXTP has recorded a 52-week high of $8.62 and a low of $0.84.
